Dosing & Uses
Dosage Forms & Strengths
tablet
- 200mcg
- 400mcg
- 600mcg
- 800mcg
- 1000mcg
- 1200mcg
- 1400mcg
- 1600mcg
Pulmonary Arterial Hypertension (PAH) Disease Progression
To delay disease and reduce risk of hospitalization for PAH (WHO Group I): 200 mcg PO BID, initially
Increase dose by 200 mcg BID, at weekly intervals (usually), to highest tolerated dose; not to exceed 1600 mcg BID
If dose not tolerated, reduce to the previous tolerated dose
Dosage Modifications
Renal impairment
- eGFR >15 mL/min/1.73 m2: No dosage adjustment required
- eGFR <15 mL/min/1.73 m2 or patients undergoing dialysis: No clinical experience
Hepatic impairment
- Mild (Child-Pugh A): No dosage adjustment required
- Moderate (Child-Pugh B): Starting dose is 200 mcg qDay; increase by increments of 200 mcg/day at weekly intervals, as tolerated
- Severe (Child-Pugh C): Avoid use
Coadministration with moderate CYP2C8 inhibitors
- Reduce selexipag dose to once daily if coadministered with moderate CYP2C8 inhibitors (eg, clopidogrel, deferasirox, teriflunomide)
- Revert back to selexipag twice daily dosing when moderated CYP2C8 inhibitor discontinued
Coadministration with CYP2C8 inducers
- Increase selexipag dose (up to 2-fold) if coadministered with rifampin
Dosage Considerations
Effectiveness was established in a long-term study in patients with PAH with WHO Functional Class II-III symptoms
Patients had idiopathic and heritable PAH (58%), PAH associated with connective-tissue disease (29%), or PAH associated with congenital heart disease with repaired shunts (10%)
Chronic Thromboembolic Pulmonary Hypertension (Orphan)
Orphan designation for chronic thromboembolic pulmonary hypertension
Orphan sponsor
- Janssen Research & Development LLC; 1820 Chapel Ave West, Suite 300; Cherry Hill, New Jersey 08002
Safety and efficacy not established
Interactions
Interaction Checker
No Results

Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor

Adverse Effects
>10%
Headache (65%)
Diarrhea (42%)
Jaw pain (26%)
Nausea (33%)
Vomiting (18%)
Pain in extremity (17%)
Myalgia (16%)
Flushing (12%)
Arthralgia (11%)
Rash (11%)
1-10%
Hemoglobin decreased below 10 g/dL (8.6%)
Anemia (8%)
Decreased appetite (6%)
Frequency Not Defined
TSH reduced (up to −0.3 MU/L from a baseline of 2.5 MU/L)
Symptomatic hypotension
Warnings
Contraindications
Concomitant use of strong CYP2C8 inhibitors (eg, gemfibrozil)
Cautions
If signs of pulmonary edema occur, consider the possibility of associated pulmonary veno-occlusive disease (PVOD); if PVOD is confirmed, discontinue selexipag
Drug interaction overview
- Contraindicated with strong CYP2C8 inhibitors; coadministration with strong CYP2C8 inhibitors may result in significant increased exposure to selexipag and its active metabolite
- Concomitant administration with an inducer of CYP2C8 and UGT 1A3 and 2B7 enzymes (rifampin) halved exposure to active metabolite; increase dose up to twice of the normal dose when coadministered with rifampin; reduce therapy dose when rifampin is stopped
- An increased selexipag dose (up to 2-fold) may be necessary if coadministered with strong CYP2C8 inducers
Pregnancy
Pregnancy
No adequate and well-controlled studies with selexipag exist in pregnant women
Animal studies
- Reproduction studies performed with selexipag showed no clinically relevant effects on embryofetal development and survival
- A slight reduction in maternal as well as in fetal body weight was observed when pregnant rats were administered selexipag during organogenesis at a dose producing an exposure ~47 times that in humans at the maximum recommended human dose
Lactation
Unknown if distributed in human breast milk
Selexipag or its metabolites were present in the milk of rats
Because many drugs are present in the human milk and because of the potential for serious adverse reactions in nursing infants, discontinue nursing or discontinue selexipag
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Selectively activates the prostacyclin receptor (ie, IP-receptor), one of 5 types of prostanoid receptors
Unlike prostacyclin analogs, selexipag is selective for the IP receptor over other prostanoid receptors (ie, EP1-4, DP, FP, TP)
Activating the IP receptor induces vasodilation and inhibits proliferation of vascular smooth muscle cells
Absorption
Peak plasma time: 1-3 hr; 3-4 hr (active metabolite)
Distribution
Protein bound: ~99% (albumin and alpha1-acid glycoprotein)
Metabolism
Undergoes enzymatic hydrolysis of the acylsulfonamide by hepatic carboxylesterase 1, to yield the active metabolite, which is ~37-fold as potent as selexipag
Elimination
Half-life: 0.8-2.5 hr; 6.2-13.5 hr (active metabolite)
Oral clearance: 35 L/hr
Excretion: 93% in feces; neither selexipag nor its metabolite were found in urine
Administration
Oral Administration
Swallow tablet whole; do not split, crush, or chew
Tolerability may be improved when taken with food
Dose interruptions and discontinuations
- If a dose is missed, patients should take a missed dose as soon as possible unless the next dose is within the next 6 hr
- If treatment is missed for ≥3 days, restart selexipag at a lower dose and then titrate to desired effect and tolerance
Storage
Store at 20-25ºC (68-77ºF)
Excursions permitted between 15-30°C (59-86°F)
Images
Patient Handout
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.